Gyre Therapeutics (GYRE) Debt/Equity Ratio: History & Chart

Gyre Therapeutics, Inc.(GYRE)

Biotechnology · San Diego, CA

$7.15-0.20 (-2.72%)

Delayed quote: Oct 6, 2026, 11:15 AM EDT

About Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.

San Diego, CA

625 employees

www.gyretx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ying Luo

View full financials

GYRE Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.03

DEBT TO EQUITY RATIO AVG TTM

0.01

DEBT TO EQUITY RATIO AVG 3Y

0.02

DEBT TO EQUITY RATIO AVG 5Y

0.02

DEBT TO EQUITY RATIO AVG 10Y

0.02

DEBT TO EQUITY RATIO AVG 15Y

0.01

DEBT TO EQUITY RATIO AVG 20Y

0.03

CURRENT VS TTM AVG

+87.91%

CURRENT VS 3Y AVG

+66.65%

CURRENT VS 5Y AVG

+46.17%

CURRENT VS 10Y AVG

+47.63%

CURRENT VS 15Y AVG

+87.91%

CURRENT VS 20Y AVG

+1.37%

SECTOR MEDIAN · HEALTHCARE

0.13

median of 585 covered companies

CURRENT VS SECTOR MEDIAN

-79.83%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Gyre Therapeutics, Inc. (GYRE)	$797.15M	0.03	0.01	0.02	0.02
Apnimed, Inc. (APMD)vs ›	$803.78M	N/A	N/A	N/A	N/A
InMode Ltd. (INMD)vs ›	$804.44M	0.01	0.01	0.01	0.01
AdaptHealth Corp. (AHCO)vs ›	$787.77M	1.50	1.31	1.32	1.45
Geron Corporation (GERN)vs ›	$785.86M	0.56	0.77	0.65	0.53
Lexicon Pharmaceuticals, Inc. (LXRX)vs ›	$781.96M	0.34	0.66	0.73	0.51
Ardelyx, Inc. (ARDX)vs ›	$818.90M	1.72	1.08	0.72	0.64
Design Therapeutics, Inc. (DSGN)vs ›	$767.91M	0.01	0.01	0.01	0.01
Mesa Laboratories, Inc. (MLAB)vs ›	$766.75M	0.54	1.02	1.03	0.84
Jade Biosciences, Inc. (JBIO)vs ›	$833.81M	0.00	0.01	0.01	0.01

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Gyre Therapeutics, Inc. (GYRE)

$797.15M

0.03

0.01

0.02

Apnimed, Inc. (APMD)vs ›

$803.78M

N/A

InMode Ltd. (INMD)vs ›

$804.44M

0.01

AdaptHealth Corp. (AHCO)vs ›

$787.77M

1.50

1.31

1.32

1.45

Geron Corporation (GERN)vs ›

$785.86M

0.56

0.77

0.65

0.53

Lexicon Pharmaceuticals, Inc. (LXRX)vs ›

$781.96M

0.34

0.66

0.73

0.51

Ardelyx, Inc. (ARDX)vs ›

$818.90M

1.72

1.08

0.72

0.64

Design Therapeutics, Inc. (DSGN)vs ›

$767.91M

0.01

Mesa Laboratories, Inc. (MLAB)vs ›

$766.75M

0.54

1.02

1.03

0.84

Jade Biosciences, Inc. (JBIO)vs ›

$833.81M

0.00

0.01

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Gyre Therapeutics, Inc. (GYRE)?

The debt to equity ratio for GYRE stock is 0.03.

Is Gyre Therapeutics, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.03 is 46% above its 5-year average of 0.02, near the low end of its 5-year range (-0.03–0.62).

What is the TTM average debt to equity ratio for Gyre Therapeutics, Inc. (GYRE)?

The TTM average debt to equity ratio for GYRE stock is 0.01.

What is the 3Y average debt to equity ratio for Gyre Therapeutics, Inc. (GYRE)?

The 3Y average debt to equity ratio for GYRE stock is 0.02.

What is the 5Y average debt to equity ratio for Gyre Therapeutics, Inc. (GYRE)?

The 5Y average debt to equity ratio for GYRE stock is 0.02.

What is the 10Y average debt to equity ratio for Gyre Therapeutics, Inc. (GYRE)?

The 10Y average debt to equity ratio for GYRE stock is 0.02.

What is the 15Y average debt to equity ratio for Gyre Therapeutics, Inc. (GYRE)?

The 15Y average debt to equity ratio for GYRE stock is 0.01.

What is the 20Y average debt to equity ratio for Gyre Therapeutics, Inc. (GYRE)?

The 20Y average debt to equity ratio for GYRE stock is 0.03.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.03
2026-03-31	0.01
2025-12-31	0.01
2025-09-30	0.01
2025-06-30	0.02
2025-03-31	0.02
2024-12-31	0.03
2024-09-30	0.03
2024-06-30	0.03
2024-03-31	0.00
2023-12-31	-0.03
2023-09-30	0.00
2023-06-30	0.00
2023-03-31	0.62
2022-12-31	0.01
2022-09-30	0.01
2022-06-30	0.02
2022-03-31	0.07
2021-12-31	0.06
2021-09-30	0.04
2021-06-30	0.03
2021-03-31	0.01
2020-12-31	0.02
2020-09-30	0.02
2020-06-30	0.01
2020-03-31	0.02
2019-12-31	0.03
2019-09-30	0.02
2019-06-30	0.02
2019-03-31	0.02
2018-12-31	0.00
2018-09-30	0.00
2018-06-30	0.00
2018-03-31	0.00
2017-12-31	0.17
2017-09-30	0.22
2017-06-30	0.19
2017-03-31	0.91
2016-12-31	1.21
2016-09-30	1.51
2016-06-30	1.29
2016-03-31	1.11
2015-12-31	1.07
2015-09-30	0.96
2015-06-30	0.00
2015-03-31	0.00
2014-12-31	0.00
2014-09-30	0.00
2014-06-30	0.01
2014-03-31	0.01
2013-12-31	0.01
2013-09-30	0.01
2013-06-30	0.01
2013-03-31	0.01
2012-12-31	0.01
2012-09-30	0.01
2012-06-30	0.01
2012-03-31	0.01
2011-12-31	0.02
2011-09-30	0.02
2011-06-30	0.02
2011-03-31	0.02
2010-12-31	0.03
2010-09-30	0.04
2010-06-30	0.03
2010-03-31	0.04
2009-12-31	0.05
2009-09-30	0.08
2009-06-30	0.09
2009-03-31	0.08
2008-12-31	0.08
2008-09-30	0.08
2008-06-30	0.07
2008-03-31	0.07
2007-12-31	0.05
2007-09-30	0.05
2007-06-30	0.06
2007-03-31	0.02
2006-12-31	0.02
2006-09-30	0.03
2006-06-30	0.04
2006-03-31	-0.01
2005-12-31	-0.01
2005-09-30	0.00
2005-06-30	0.00
2005-03-31	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.03

2026-03-31

0.01

2025-12-31

0.01

2025-09-30

0.01

2025-06-30

0.02

2025-03-31

0.02

2024-12-31

0.03

2024-09-30

0.03

2024-06-30

0.03

2024-03-31

0.00

2023-12-31

-0.03

2023-09-30

0.00

2023-06-30

0.00

2023-03-31

0.62

2022-12-31

0.01

2022-09-30

0.01

2022-06-30

0.02

2022-03-31

0.07

2021-12-31

0.06

2021-09-30

0.04

2021-06-30

0.03

2021-03-31

0.01

2020-12-31

0.02

2020-09-30

0.02

2020-06-30

0.01

2020-03-31

0.02

2019-12-31

0.03

2019-09-30

0.02

2019-06-30

0.02

2019-03-31

0.02

2018-12-31

0.00

2018-09-30

0.00

2018-06-30

0.00

2018-03-31

0.00

2017-12-31

0.17

2017-09-30

0.22

2017-06-30

0.19

2017-03-31

0.91

2016-12-31

1.21

2016-09-30

1.51

2016-06-30

1.29

2016-03-31

1.11

2015-12-31

1.07

2015-09-30

0.96

2015-06-30

0.00

2015-03-31

0.00

2014-12-31

0.00

2014-09-30

0.00

2014-06-30

0.01

2014-03-31

0.01

2013-12-31

0.01

2013-09-30

0.01

2013-06-30

0.01

2013-03-31

0.01

2012-12-31

0.01

2012-09-30

0.01

2012-06-30

0.01

2012-03-31

0.01

2011-12-31

0.02

2011-09-30

0.02

2011-06-30

0.02

2011-03-31

0.02

2010-12-31

0.03

2010-09-30

0.04

2010-06-30

0.03

2010-03-31

0.04

2009-12-31

0.05

2009-09-30

0.08

2009-06-30

0.09

2009-03-31

0.08

2008-12-31

0.08

2008-09-30

0.08

2008-06-30

0.07

2008-03-31

0.07

2007-12-31

0.05

2007-09-30

0.05

2007-06-30

0.06

2007-03-31

0.02

2006-12-31

0.02

2006-09-30

0.03

2006-06-30

0.04

2006-03-31

-0.01

2005-12-31

-0.01

2005-09-30

0.00

2005-06-30

0.00

2005-03-31

0.00

Debt to Equity Ratio: 0.03

GYRE Debt to Equity Ratio

GYRE Average Debt to Equity Ratio Chart

GYRE Current vs Average Debt to Equity Ratio Chart

GYRE Debt to Equity Ratio Metrics

GYRE Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

GYRE Debt to Equity Ratio History

Related Metrics